Verastem (VSTM) Projected to Post Quarterly Earnings on Thursday

Verastem (NASDAQ:VSTM - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $0.10 million for the quarter.

Verastem (NASDAQ:VSTM - Get Free Report) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.57). On average, analysts expect Verastem to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Verastem Trading Down 6.8 %

NASDAQ:VSTM traded down $0.48 on Tuesday, reaching $6.53. 1,247,472 shares of the company's stock were exchanged, compared to its average volume of 1,041,496. The business has a fifty day moving average of $6.28 and a 200-day moving average of $5.39. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 2.77. Verastem has a 52-week low of $2.10 and a 52-week high of $13.52. The firm has a market capitalization of $336.23 million, a price-to-earnings ratio of -2.05 and a beta of 0.85.

Analysts Set New Price Targets

VSTM has been the subject of several recent research reports. Guggenheim raised their price target on shares of Verastem from $13.00 to $14.00 and gave the company a "buy" rating in a research report on Monday, March 24th. B. Riley boosted their price objective on Verastem from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Jefferies Financial Group began coverage on shares of Verastem in a research note on Thursday, April 10th. They issued a "buy" rating and a $15.00 price target for the company. Royal Bank of Canada reduced their price objective on shares of Verastem from $16.00 to $14.00 and set an "outperform" rating on the stock in a report on Friday, March 21st. Finally, HC Wainwright increased their target price on Verastem from $7.00 to $10.00 and gave the company a "buy" rating in a report on Monday, March 24th. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $13.89.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.